Advanced search
Publication Cover
Bioengineered Volume 12, 2021 - Issue 1
Submit an article Journal homepage
1,609
Views
3
CrossRef citations to date
0
Altmetric
Research Paper

Incomplete thermal ablation-induced up-regulation of transcription factor nuclear receptor subfamily 2, group F, member 6 (NR2F6) contributes to the rapid progression of residual liver tumor in hepatoblastoma

Jin-shu Panga Department of Medical Ultrasonics, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P.R. ChinaView further author information
,
Dong-yue Wena Department of Medical Ultrasonics, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P.R. ChinaView further author information
,
Rong-quan Heb Department of Medical Oncology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P.R. ChinaView further author information
,
Gang Chenc Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P.R. ChinaView further author information
,
Peng Lina Department of Medical Ultrasonics, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P.R. ChinaView further author information
,
Jin-hong Lia Department of Medical Ultrasonics, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P.R. ChinaView further author information
,
Yu-jia Zhaoa Department of Medical Ultrasonics, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P.R. ChinaView further author information
,
Lin-Yong Wua Department of Medical Ultrasonics, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P.R. ChinaView further author information
,
Jun-Hong Chend Department of Pathology, Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi Zhuang Autonomous Region, P.R. ChinaView further author information
,
Yun Hea Department of Medical Ultrasonics, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P.R. ChinaView further author information
,
Li-Ting Qinc Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P.R. ChinaView further author information
,
Jia-bo Chene Department of Pediatric Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P.R. ChinaView further author information
,
Yong Lie Department of Pediatric Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P.R. ChinaView further author information
&
Hong Yanga Department of Medical Ultrasonics, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P.R. ChinaCorrespondence[email protected]
View further author information
 show all
Pages 4289-4303 | Received 18 Apr 2021, Accepted 15 Jun 2021, Published online: 24 Jul 2021

References

  • Sharma D, Subbarao G, Saxena R. Hepatoblastoma. Semin Diagn Pathol. 2017;34(2):192–200. Epub 2017/01/28. PubMed PMID: 28126357.
  • Ranganathan S, Lopez-Terrada D, Alaggio R. Hepatoblastoma and pediatric hepatocellular carcinoma: an update. Pediatr Dev Pathol. 2020;23(2):79–95. Epub 2019/09/27. PubMed PMID: 31554479.
  • Czauderna P, Lopez-Terrada D, Hiyama E, et al. Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy. Curr Opin Pediatr. 2014;26(1):19–28. Epub 2013/12/11. PubMed PMID: 24322718.
  • Benson AB, D’Angelica MI, Abbott DE, et al. Guidelines Insights: hepatobiliary Cancers, Version 2.2019. J Natl Compr Canc Netw. 2019;17(4):302–310. Epub 2019/04/09. PubMed PMID: 30959462.
  • Perilongo G, Maibach R, Shafford E, et al. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009;361(17):1662–1670. Epub 2009/10/23. PubMed PMID: 19846851.
  • Roebuck DJ, Aronson D, Clapuyt P, et al. 2005 PRETEXT: a revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group. Pediatr Radiol. 2007;37(2):123–132. quiz 249–50. Epub 2006/12/23. PubMed PMID: 17186233; PubMed Central PMCID: PMCPMC1805044.
  • Yevich S, Calandri M, Gravel G, et al. Reiterative radiofrequency ablation in the management of pediatric patients with hepatoblastoma metastases to the lung, liver, or bone. Cardiovasc Intervent Radiol. 2019;42(1):41–47. Epub 2018/10/24. PubMed PMID: 30350173.
  • European Association for the Study of the Liver. Electronic address eee, European Association for the study of the L. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. doi: 10.1016/j.jhep.2018.03.019. Epub 2018/04/10. PubMed PMID: 29628281.
  • Zhang R, Yao RR, Li JH, et al. Activated hepatic stellate cells secrete periostin to induce stem cell-like phenotype of residual hepatocellular carcinoma cells after heat treatment. Sci Rep. 2017;7(1):2164. Epub 2017/05/21. PubMed PMID: 28526827; PubMed Central PMCID: PMCPMC5438402.
  • Schnapauff D, Collettini F, Steffen I, et al. Activity-based cost analysis of hepatic tumor ablation using CT-guided high-dose rate brachytherapy or CT-guided radiofrequency ablation in hepatocellular carcinoma. Radiat Oncol. 2016;11(1):26. Epub 2016/02/26. PubMed PMID: 26911437; PubMed Central PMCID: PMCPMC4766654.
  • Jiang Y, Zhou S, Shen G, et al. Microwave ablation combined with transcatheter arterial chemoembolization is effective for treating unresectable hepatoblastoma in infants and children. Medicine (Baltimore). 2018;97(42):e12607. Epub 2018/10/20. PubMed PMID: 30334945; PubMed Central PMCID: PMCPMC6211922.
  • Jiang T, Zhang X, Ding J, et al. Inflammation and cancer: inhibiting the progression of residual hepatic VX2 carcinoma by anti-inflammatory drug after incomplete radiofrequency ablation. Int J Clin Exp Pathol. 2015 Epub 2016/01/30. PubMed PMID: 26823706; PubMed Central PMCID: PMCPMC4713492;8(11):13945–13956.
  • Cui R, Yu J, Gu Y, et al. Microwave ablation assisted by three-dimensional visualization system as local therapy for relapsed hepatoblastoma: a small pilot study. Abdom Radiol (NY). 2019;44(8):2909–2915. Epub 2019/05/16. PubMed PMID: 31089779.
  • Liu B, Zhou L, Huang G, et al. First experience of ultrasound-guided percutaneous ablation for recurrent hepatoblastoma after liver resection in children. Sci Rep. 2015;5(1):16805. Epub 2015/11/19. PubMed PMID: 26578035; PubMed Central PMCID: PMCPMC4649467.
  • Zhou B, Jia L, Zhang Z, et al. The nuclear orphan receptor NR2F6 promotes hepatic steatosis through upregulation of fatty acid transporter CD36. Adv Sci (Weinh). 2020;7(21):2002273. Epub 2020/11/12. PubMed PMID: 33173745; PubMed Central PMCID: PMCPMC7610302.
  • Zhang J, Meng H, Zhang M, et al. Regulation of docetaxel chemosensitivity by NR2F6 in breast cancer. Endocr Relat Cancer. 2020;27(5):309–323. Epub 2020/03/24. PubMed PMID: 32203934.
  • Mai J, Zhong ZY, Guo GF, et al. Polo-Like Kinase 1 phosphorylates and stabilizes KLF4 to promote tumorigenesis in nasopharyngeal carcinoma. Theranostics. 2019;9(12):3541–3554. Epub 2019/07/10. PubMed PMID: 31281496; PubMed Central PMCID: PMCPMC6587166.
  • Klepsch V, Pommermayr M, Humer D, et al. Targeting the orphan nuclear receptor NR2F6 in T cells primes tumors for immune checkpoint therapy. Cell Commun Signal. 2020;18(1):8. Epub 2020/01/16. PubMed PMID: 31937317; PubMed Central PMCID: PMCPMC6961368.
  • Klapper L, Ribbat-Idel J, Kuppler P, et al. NR2F6 as a prognostic biomarker in HNSCC. Int J Mol Sci. 2020;21(15):5527. Epub 2020/08/06. PubMed PMID: 32752295; PubMed Central PMCID: PMCPMC7432340.
  • Klepsch V, Hermann-Kleiter N, Do-Dinh P, et al. Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade. Nat Commun. 2018;9(1):1538. doi: 10.1038/s41467-018-04004-2. Epub 2018/04/20. PubMed PMID: 29670099; PubMed Central PMCID: PMCPMC5906604.
  • Zhang R, Mo WJ, Huang LS, et al. Identifying the prognostic risk factors of synaptojanin 2 and its underlying perturbations pathways in hepatocellular carcinoma. Bioengineered. 2021;12(1):855–874. Epub 2021/03/02. PubMed PMID: 33641617.
  • Wang XD, Peng JB, Zhou CY, et al. Potential therapies for residual hepatoblastoma following incomplete ablation treatment in a nude mouse subcutaneous xenograft model based on lncRNA and mRNA expression profiles. Oncol Rep. 2020;43(6):1915–1927. Epub 2020/03/19. PubMed PMID: 32186781; PubMed Central PMCID: PMCPMC7160554.
  • Zhao Z, Wu J, Liu X, et al. Insufficient radiofrequency ablation promotes proliferation of residual hepatocellular carcinoma via autophagy. Cancer Lett. 2018;421:73–81. Epub 2018/02/20. PubMed PMID: 29458142.
  • Kong J, Yao C, Dong S, et al. ICAM-1 activates platelets and promotes endothelial permeability through VE-Cadherin after insufficient radiofrequency ablation. Adv Sci (Weinh). 2021;8(4):2002228. Epub 2021/03/02. PubMed PMID: 33643788; PubMed Central PMCID: PMCPMC7887603.
  • Su T, Huang M, Liao J, et al. Insufficient radiofrequency ablation promotes hepatocellular carcinoma metastasis through m(6) A mRNA methylation dependent mechanism. Hepatology. 2021. doi: 10.1002/hep.31766.. Epub 2021/02/28. PubMed PMID: 33638162.
  • Li XJ, Pang JS, Li YM, et al. Clinical value of survivin and its underlying mechanism in ovarian cancer: a bioinformatics study based on GEO and TCGA data mining. Pathol Res Pract. 2018;214(3):385–401. Epub 2018/03/04. PubMed PMID: 29499854.
  • Chen YJ, Guo YN, Shi K, et al. Down-regulation of microRNA-144-3p and its clinical value in non-small cell lung cancer: a comprehensive analysis based on microarray, miRNA-sequencing, and quantitative real-time PCR data. Respir Res. 2019;20(1):48. Epub 2019/03/06. PubMed PMID: 30832674; PubMed Central PMCID: PMCPMC6399847.
  • Mei S, Qin Q, Wu Q, et al. Cistrome data browser: a data portal for ChIP-Seq and chromatin accessibility data in human and mouse. Nucleic Acids Res. 2017;45(D1):D658–D62. doi: 10.1093/nar/gkw983. Epub 2016/10/30. doi: PubMed PMID: 27789702; PubMed Central PMCID: PMCPMC5210658.
  • Liao Y, Wang J, Jaehnig EJ, et al. WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs. Nucleic Acids Res. 2019;47(W1):W199–W205. Epub 2019/05/23. PubMed PMID: 31114916; PubMed Central PMCID: PMCPMC6602449.
  • Wu Y, Qi H, Cao F, et al. TACE-Sorafenib with thermal ablation has survival benefits in patients with huge unresectable hepatocellular carcinoma. Front Pharmacol. 2020;11:1130. Epub 2020/09/10. PubMed PMID: 32903854; PubMed Central PMCID: PMCPMC7438914.
  • Wu D, Yang Y, Chen J, et al. Three different ways of treating primary hepatocellular carcinoma at an early stage: a prospective comparative study. Gastroenterol Res Pract Epub 2020/06/09. PubMed PMID: 32508913; PubMed Central PMCID: PMCPMC7245688. 2020;2020:7802498.
  • Dou JP, Wu Q, Fu CH, et al. Amplified intracellular Ca(2+) for synergistic anti-tumor therapy of microwave ablation and chemotherapy. J Nanobiotechnology. 2019;17(1):118. Epub 2019/12/04. PubMed PMID: 31791353; PubMed Central PMCID: PMCPMC6889637.
  • Li X, An C, Liu F, et al. The value of 3D visualization operative planning system in ultrasound-guided percutaneous microwave ablation for large hepatic hemangiomas: a clinical comparative study. BMC Cancer. 2019;19(1):550. Epub 2019/06/09. PubMed PMID: 31174503; PubMed Central PMCID: PMCPMC6555953.
  • Jing X, Zhou Y, Ding J, et al. The learning curve for thermal ablation of liver cancers: 4,363-session experience for a single central in 18 Years. Front Oncol. 2020;10:540239. Epub 2020/11/17. PubMed PMID: 33194601; PubMed Central PMCID: PMCPMC7606932.
  • Kong P, Pan H, Yu M, et al. Insufficient microwave ablation-induced promotion of distant metastasis is suppressed by β-catenin pathway inhibition in breast cancer. Oncotarget. 2017;8(70):115089–115101. Epub 2018/02/01. doi: 10.18632/oncotarget.22859. PubMed PMID: 29383144; PubMed Central PMCID: PMCPMC5777756.
  • Zhang N, Li H, Qin C, et al. Insufficient radiofrequency ablation promotes the metastasis of residual hepatocellular carcinoma cells via upregulating flotillin proteins. J Cancer Res Clin Oncol. 2019;145(4):895–907. Epub 2019/03/02. PubMed PMID: 30820716; PubMed Central PMCID: PMCPMC6435628.
  • Zhang N, Zhu H, Dong YH, et al. Establishment of an insufficient radiofrequency ablation orthotopic nude mouse model of hepatocellular carcinoma to study the invasiveness and metastatic potential of residual cancer. Oncol Lett. 2019;18(3):2548–2553. Epub 2019/08/14. PubMed PMID: 31402950; PubMed Central PMCID: PMCPMC6676705.
  • Jondal DE, Thompson SM, Butters KA, et al. Heat stress and hepatic laser thermal ablation induce hepatocellular carcinoma growth: role of PI3K/mTOR/AKT Signaling. Radiology. 2018;288(3):730–738. Epub 2018/05/09. PubMed PMID: 29737948; PubMed Central PMCID: PMCPMC6122226.
  • Jiang AN, Liu JT, Zhao K, et al. Specific inhibitor of matrix metalloproteinase decreases tumor invasiveness after radiofrequency ablation in liver tumor animal model. Front Oncol. 2020;10:561805. Epub 2020/12/18. PubMed PMID: 33330030; PubMed Central PMCID: PMCPMC7709861.
  • Xu WL, Wang SH, Sun WB, et al. Insufficient radiofrequency ablation-induced autophagy contributes to the rapid progression of residual hepatocellular carcinoma through the HIF-1alpha/BNIP3 signaling pathway. BMB Rep. 2019;52(4):277–282. Epub 2019/04/04. PubMed PMID: 30940322; PubMed Central PMCID: PMCPMC6507849.
  • Dhiman VK, Bolt MJ, White KP. Nuclear receptors in cancer - uncovering new and evolving roles through genomic analysis. Nat Rev Genet. 2018;19(3):160–174. Epub 2017/12/28. PubMed PMID: 29279606..
  • Levin ER, Hammes SR. Nuclear receptors outside the nucleus: extranuclear signalling by steroid receptors. Nat Rev Mol Cell Biol. 2016;17(12):783–797. Epub 2016/11/04. PubMed PMID: 27729652; PubMed Central PMCID: PMCPMC5649368.
  • Evans RM, Mangelsdorf DJ. Nuclear receptors, RXR, and the big bang. Cell. 2014;157(1):255–266. Epub 2014/04/01. PubMed PMID: 24679540; PubMed Central PMCID: PMCPMC4029515.
  • Kojetin DJ, Burris TP. REV-ERB and ROR nuclear receptors as drug targets. Nat Rev Drug Discov. 2014;13(3):197–216. Epub 2014/03/01. PubMed PMID: 24577401; PubMed Central PMCID: PMCPMC4865262.
  • Kenda M, Sollner Dolenc M. Computational study of drugs targeting nuclear receptors. Molecules. 2020;25(7):1616. doi: 10.3390/molecules25071616. Epub 2020/04/05. PubMed PMID: 32244747; PubMed Central PMCID: PMCPMC7180905.
  • Tao Z, Li S, Ichim TE, et al. Cellular immunotherapy of cancer: an overview and future directions. Immunotherapy. 2017;9(7):589–606. Epub 2017/06/10. PubMed PMID: 28595516.
  • Liu J, Li T, Liu XL. DDA1 is induced by NR2F6 in ovarian cancer and predicts poor survival outcome. Eur Rev Med Pharmacol Sci. 2017;21(6): 1206–1213. Epub 2017/04/08. PubMed PMID: 28387912.
  • Wang L, Long H, Zheng Q, et al. Circular RNA circRHOT1 promotes hepatocellular carcinoma progression by initiation of NR2F6 expression. Mol Cancer. 2019;18(1):119. Epub 2019/07/22. PubMed PMID: 31324186; PubMed Central PMCID: PMCPMC6639939.
  • Bonta PI, van Tiel CM, Vos M, et al. Nuclear receptors Nur77, Nurr1, and NOR-1 expressed in atherosclerotic lesion macrophages reduce lipid loading and inflammatory responses. Arterioscler Thromb Vasc Biol. 2006;26(10):2288–2294. Epub 2006/07/29. PubMed PMID: 16873729.
  • Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. Epub 2011/03/08. PubMed PMID: 21376230.
  • Luo X, Cheng C, Tan Z, et al. Emerging roles of lipid metabolism in cancer metastasis. Mol Cancer. 2017;16(1):76. Epub 2017/04/13. PubMed PMID: 28399876; PubMed Central PMCID: PMCPMC5387196.
  • Barrera G, Pizzimenti S, Dianzani MU. Lipid peroxidation: control of cell proliferation, cell differentiation and cell death. Mol Aspects Med. 2008;29(1–2):1–8. Epub 2007/11/27. PubMed PMID: 18037483.
  • Rysman E, Brusselmans K, Scheys K, et al. De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. Cancer Res. 2010;70(20):8117–8126. Epub 2010/09/30. PubMed PMID: 20876798.
  • Nelson ME, Lahiri S, Chow JD, et al. Inhibition of hepatic lipogenesis enhances liver tumorigenesis by increasing antioxidant defence and promoting cell survival. Nat Commun. 2017;8(1):14689. doi: 10.1038/ncomms14689. Epub 2017/03/16. PubMed PMID: 28290443; PubMed Central PMCID: PMCPMC5424065.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.